Insomnia Treatment in Adults: 8 Essential Clinical Rules
Clinical Practice Update — CBT-I, Pharmacotherapy, and Safe Deprescribing in Primary Care
This is an original clinical education article informed by current guidelines and evidence. See References below for source documents.
- Clinical Focus
- Evidence-based insomnia treatment in adults managed in primary care
- Target Audience
- Family physicians, general practitioners, nurse practitioners, physician assistants, pharmacists
- Setting
- Primary care and outpatient family medicine
- Source Evidence
- •AASM Clinical Practice Guideline — Pharmacologic Treatment of Chronic Insomnia (Sateia et al., 2017)
- •AASM Clinical Practice Guideline — Behavioral and Psychological Treatments for Chronic Insomnia (Edinger et al., 2021)
- •ACP Clinical Practice Guideline — Management of Chronic Insomnia Disorder (Qaseem et al., 2016)
- •European Insomnia Guideline Update (Riemann et al., 2023)
Key Clinical Takeaways
Effective insomnia treatment begins with accurate diagnosis, followed by cognitive behavioural therapy for insomnia (CBT-I) as the first-line intervention for chronic insomnia disorder in adults. Medication has a role — but not the role many prescribers default to. This Practice Update distils current AASM, ACP, and European guideline evidence into the decisions that matter during a primary care appointment on insomnia treatment.
- 1Diagnose chronic insomnia clinically — symptoms 3+ nights weekly, for 3+ months, with daytime impact; routine polysomnography is not indicated → Diagnosis
- 2Always screen for sleep apnea, restless legs, depression, chronic pain, and substance use before prescribing a hypnotic → Diagnosis
- 3Offer CBT-I as first-line for chronic insomnia in adults — digital CBT-I and brief behavioural therapy are acceptable alternatives → CBT-I
- 4When medication is needed, prefer a DORA (suvorexant, lemborexant, daridorexant) or low-dose doxepin over Z-drugs and benzodiazepines → Medications
- 5Melatonin and low-dose trazodone have weak evidence for chronic insomnia — do not present them as proven therapy → Medications
- 6Avoid diphenhydramine, doxylamine, and other sedating antihistamines for insomnia in older adults — they appear on Beers Criteria → Special Populations
- 7Use all hypnotics at the lowest effective dose, ideally for under 4 weeks, with a documented reassessment date → Deprescribing
- 8Taper chronic Z-drugs and benzodiazepines slowly — combine tapering with CBT-I for the highest chance of durable discontinuation → Deprescribing
Diagnosing Chronic Insomnia Before Starting Insomnia Treatment
The most common error in insomnia treatment is prescribing a hypnotic without a proper diagnosis. “Trouble sleeping” is a symptom, not a condition. Chronic insomnia disorder is a clinical diagnosis based on DSM-5 and ICSD-3 criteria: difficulty initiating or maintaining sleep, occurring at least three nights per week, for at least three months, with daytime consequences — fatigue, impaired function, mood disturbance, or sleepiness. Getting the diagnosis right is the foundation of effective insomnia treatment.
Diagnose chronic insomnia clinically using DSM-5 or ICSD-3 criteria. Routine polysomnography is not indicated unless another sleep disorder is suspected. Use the Insomnia Severity Index (ISI) to quantify severity at baseline and track response.
Strong Rec High Evidence AASM 2017 Edinger 2021Screen for contributing and mimicking conditions before initiating insomnia treatment: obstructive sleep apnea (STOP-BANG), restless legs syndrome, depression (PHQ-9), chronic pain, caffeine and alcohol use, and evening stimulants including nicotine and medications such as bupropion or pseudoephedrine.
Strong Rec Moderate Evidence AASM 2017 Riemann 2023Ask the patient to keep a sleep diary for 1–2 weeks before committing to a treatment plan. The diary often reveals a correctable behavioural pattern — irregular schedule, long naps, caffeine timing, excessive time in bed — that makes prescribing unnecessary.
Moderate Rec Moderate Evidence Edinger 2021Red Flags That Change the Plan
| Presenting Feature | Suspected Diagnosis | Next Step | Why It Changes Management |
|---|---|---|---|
| Loud snoring, witnessed apneas, BMI over 30, morning headache | Obstructive sleep apnea | STOP-BANG, refer for sleep study | Sedatives worsen OSA and risk respiratory events |
| Uncomfortable leg sensations at rest, relieved by movement | Restless legs syndrome | Check ferritin; treat RLS directly | Hypnotics do not address the sensory symptoms |
| Anhedonia, low mood, early morning waking | Major depressive disorder | PHQ-9, treat depression | Sleep improves with effective antidepressant therapy |
| Symptoms only on work nights, better on weekends | Shift work disorder or insufficient sleep syndrome | Address schedule and sleep opportunity | Different condition with different management |
| Excessive daytime sleepiness with cataplexy | Narcolepsy | Refer to sleep specialist | Requires specialist evaluation and MSLT |
CBT-I: The First-Line Choice for Insomnia Treatment
Every major guideline — AASM, ACP, and the European Sleep Research Society — agrees that cognitive behavioural therapy for insomnia is the first-line insomnia treatment for chronic insomnia disorder in adults. Effect sizes are comparable to short-term pharmacotherapy, the benefits last after the intervention ends, and there are no medication harms. Starting insomnia treatment with CBT-I rather than a prescription also sets expectations correctly for the long game.
Offer CBT-I to every adult with chronic insomnia disorder before any hypnotic is prescribed. A typical course is 4–8 weekly sessions combining sleep restriction, stimulus control, cognitive restructuring, and sleep hygiene.
Strong Rec High Evidence AASM 2021 ACP 2016Recommend an evidence-based digital CBT-I programme (e.g., Sleepio, Somryst, SHUTi) when in-person therapy is not accessible. Digital delivery has reproducible effect sizes in randomised trials and scales where therapist capacity does not.
Moderate Rec High Evidence Edinger 2021Consider a brief behavioural therapy for insomnia (BBTI) protocol delivered over 2–4 sessions in primary care. BBTI focuses on stimulus control and sleep restriction — the two components with the largest individual effect sizes.
Moderate Rec Moderate Evidence Edinger 2021The Core Components of CBT-I Explained
| Component | What the Patient Does | How to Explain It | Common Pitfall |
|---|---|---|---|
| Sleep restriction | Compress time in bed to match actual sleep time, then slowly expand | “We’ll build up sleep pressure so bed becomes where sleep happens” | Patients stop in the first week when they feel worse |
| Stimulus control | Get out of bed if awake 20+ minutes; only use bed for sleep and sex | “We’re rebuilding the bed-sleep association your brain has lost” | Ignoring the rule during travel or illness |
| Cognitive therapy | Challenge catastrophic thoughts about sleep loss | “Worrying about sleep is what keeps you awake, not the hour on the clock” | Clinicians skip it; it is often the highest-yield component |
| Sleep hygiene | Caffeine and alcohol timing, bedroom environment, wind-down routine | “These are the baseline conditions — necessary but not sufficient” | Delivering hygiene alone and calling it CBT-I |
| Relaxation training | Progressive muscle relaxation, paced breathing, imagery | “A tool for the pre-sleep window, not a cure” | Using it as the only intervention |
Pharmacological Insomnia Treatment Options
When a medication is required as part of insomnia treatment — because CBT-I is not available, the patient declines it, or severe symptoms warrant a bridge — choose the agent that matches the dominant complaint (onset versus maintenance) and carries the most favourable safety profile. The dual orexin receptor antagonists (DORAs) have emerged in recent guideline updates as the preferred chronic insomnia option where cost and access allow.
Prescribe a DORA (lemborexant 5–10 mg, suvorexant 10–20 mg, daridorexant 25–50 mg) as the preferred pharmacological choice for chronic insomnia in adults when cost and formulary allow. DORAs improve onset and maintenance with less morning impairment than benzodiazepines or Z-drugs.
Moderate Rec High Evidence AASM 2017 Riemann 2023Prescribe low-dose doxepin (3–6 mg at bedtime) when sleep-maintenance insomnia is dominant. At these low doses it is a selective H1 antihistamine, with minimal anticholinergic burden and solid evidence for reducing wake-after-sleep-onset.
Moderate Rec Moderate Evidence AASM 2017Use Z-drugs (zolpidem, eszopiclone, zaleplon) at the lowest effective dose, for the shortest period, with a defined reassessment date. Counsel on parasomnias, next-day impairment, and falls — especially with zolpidem, which carries FDA boxed warnings for complex sleep behaviours.
Conditional Rec Moderate Evidence AASM 2017 FDA 2019Do not use diphenhydramine, doxylamine, or hydroxyzine as routine insomnia treatment in older adults. Anticholinergic burden, next-day grogginess, fall risk, and tachyphylaxis within days make these agents inappropriate for chronic use — they appear on the AGS Beers Criteria.
Against Moderate Evidence AGS Beers 2023Do not prescribe trazodone or quetiapine as first-line off-label insomnia treatment. Both are widely used for this purpose; neither has high-quality evidence for chronic insomnia, and both carry adverse effect profiles (orthostasis, priapism, metabolic, QT) that outweigh any sleep benefit.
Against Low Evidence AASM 2017Discuss melatonin honestly. It is not a proven treatment for chronic insomnia in adults (effect sizes are small and inconsistent). It has a better evidence base for circadian phase disorders such as jet lag, shift work, and delayed sleep phase. If used, prefer 0.3–1 mg given 1–2 hours before bedtime — the physiological dose, not the mega-doses sold over the counter.
Conditional Rec Low Evidence AASM 2017Pharmacological Options for Insomnia Treatment: A Drug-by-Drug Guide
| Drug | Typical Dose | Best Suited For | Practical Tips and Cautions |
|---|---|---|---|
| Lemborexant (DORA) | 5–10 mg at bedtime | Onset and maintenance; older adults | Caution with strong CYP3A inhibitors. Morning alertness favoured over suvorexant. |
| Daridorexant (DORA) | 25–50 mg at bedtime | Chronic insomnia; daytime function a priority | Approved by FDA in 2022. Lower residual sedation. CYP3A substrate. |
| Suvorexant (DORA) | 10–20 mg at bedtime | Onset and maintenance | Longer half-life — next-day drowsiness possible. Contraindicated in narcolepsy. |
| Low-dose doxepin | 3–6 mg at bedtime | Sleep maintenance; cost-sensitive choice | Avoid higher (antidepressant) doses for insomnia. Take 30 minutes before bed on empty stomach. |
| Zolpidem | 5 mg (women/older) to 10 mg | Onset insomnia, short-term bridge | FDA boxed warning for complex sleep behaviour. Cut doses in half for women and older adults. |
| Eszopiclone | 1–3 mg at bedtime | Maintenance insomnia | Metallic taste is common. Lower starting dose in older adults (1 mg). |
| Ramelteon | 8 mg at bedtime | Onset insomnia; low-harm profile | Weak effect size. No dependence risk. Avoid with fluvoxamine. |
| Melatonin (OTC) | 0.3–1 mg, 1–2h pre-bed | Circadian problems more than pure insomnia | OTC formulations often 3–10 mg — supraphysiological and no more effective. |
| Trazodone (off-label) | 25–100 mg at bedtime | Limited role; not first-line | Priapism risk in men. Orthostatic hypotension. Evidence for chronic use is weak. |
| Temazepam/triazolam (benzo) | Lowest effective dose, <4 weeks | Short-term crisis bridge only | Avoid in older adults. Never combine with opioids. Document end-date at prescription. |
Clinical Decision Pathway
A practical, question-based approach to insomnia treatment in a 15-minute primary care slot. Work through the questions in order — each answer narrows the insomnia treatment plan to something you can implement the same visit.
Deprescribing and Safe Duration of Insomnia Treatment
The hardest part of insomnia treatment is often what to do with the patient already taking a hypnotic. Inherited long-term benzodiazepine and Z-drug prescriptions are extremely common in primary care, and stopping is uncomfortable — for patient and prescriber alike. A structured, shared-decision approach with concurrent CBT-I gives the highest chance of durable discontinuation.
Initiate gradual tapering of long-term Z-drugs and benzodiazepine hypnotics. Reduce by 10–25% of the original dose every 2–4 weeks, slowing further if withdrawal symptoms emerge. Tapering over 8–24 weeks is common and acceptable.
Strong Rec Moderate Evidence AASM 2017 Choosing WiselyPair every deprescribing attempt with concurrent CBT-I. Randomised trials show that adding CBT-I during the taper doubles sustained discontinuation rates at 6–12 months compared with taper alone.
Strong Rec High Evidence Edinger 2021Document a reassessment date at the time any hypnotic is prescribed. Limit initial scripts to 2–4 weeks of insomnia treatment and require an in-person review before any refill. Standing PRN prescriptions are an anti-pattern.
Strong Rec Low Evidence Choosing WiselyA Practical Z-Drug and Benzodiazepine Tapering Schedule
| Step | Action | What to Expect | When to Slow Down |
|---|---|---|---|
| 1. Set-up | Shared decision, write plan in the chart, start sleep diary | Patient anxiety about taper is normal | Defer if active crisis or major life event |
| 2. First reduction | Reduce 10–25% of original dose; hold for 2–4 weeks | Mild rebound insomnia days 2–7 is common | Severe anxiety, autonomic symptoms → pause |
| 3. Serial reductions | Repeat reductions every 2–4 weeks with CBT-I in parallel | Sleep latency variable during taper; stabilises over weeks | Rebound persists > 2 weeks → smaller steps |
| 4. Final phase | Small final reductions (e.g., 1–2 mg zolpidem at a time) | Final step is often the hardest; use compounding if needed | Cross to equivalent diazepam if stuck |
| 5. Maintenance | ISI at 3, 6, 12 months after stop | Around 60–70% remain off with CBT-I support | Rising ISI → reinforce CBT-I, don’t immediately re-prescribe |
Evidence in Context
Where the major guidelines on insomnia treatment agree, where they differ, and where the evidence is still evolving — particularly for DORAs, melatonin, and off-label agents in chronic insomnia treatment.
Where AASM, ACP, and the European Guideline Agree
All three bodies place CBT-I unambiguously as the first-line insomnia treatment for chronic insomnia disorder, endorse a stepped-care model, and caution against long-term benzodiazepine use. They agree that routine polysomnography is not indicated for uncomplicated insomnia, and that medication, when used, should be at the lowest effective dose for the shortest time necessary.
Where They Differ: DORA Positioning
The AASM 2017 pharmacologic guideline predated daridorexant approval and gives conditional recommendations for suvorexant. The 2023 European update places DORAs more prominently in chronic insomnia treatment given accumulating long-term safety data, whereas older ACP guidance (2016) does not address DORAs at all. When explaining choices to patients, acknowledge that preferred options have shifted as evidence has matured.
Melatonin: What the Evidence Actually Shows
Meta-analyses consistently show small, often clinically inconsequential benefits of melatonin for chronic insomnia in adults — latency reductions of around 7–10 minutes. Effect sizes are substantially larger in circadian disorders (jet lag, delayed sleep phase) and in children with neurodevelopmental conditions. Quality control of OTC preparations in the United States is poor — one analysis found actual content varying from 17% to 478% of label claim — a point worth mentioning when patients insist it must work because it’s “natural”.
CBT-I Versus Pharmacotherapy: Head-to-Head
Direct comparisons show CBT-I and hypnotic pharmacotherapy produce similar short-term improvements in sleep onset latency and wake-after-sleep-onset. The durability advantage is CBT-I’s: benefits persist 6–24 months after the intervention ends, whereas stopping a hypnotic typically returns symptoms within weeks. This is the single most persuasive point to communicate to patients who resist CBT-I because it is “slower”.
What We Still Don’t Know
Long-term (over 1 year) safety and efficacy of DORAs remain less well characterised than for older agents. The optimal duration of intermittent or PRN hypnotic dosing in chronic insomnia is still uncertain. The place of cannabinoid products, widely used by patients but unevenly studied, is an open question. Emerging digital-first CBT-I pathways appear promising but heterogeneous in quality and regulatory status.
References
- 1.Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(2):307–349. doi:10.5664/jcsm.6470
- 2.Edinger JD, Arnedt JT, Bertisch SM, et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(2):255–262. doi:10.5664/jcsm.8986
- 3.Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2016;165(2):125–133. doi:10.7326/M15-2175
- 4.Riemann D, Espie CA, Altena E, et al. The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023. J Sleep Res. 2023;32(6):e14035. doi:10.1111/jsr.14035
- 5.By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052–2081. doi:10.1111/jgs.18372
- 6.US Food and Drug Administration. FDA adds Boxed Warning for risk of serious injuries caused by sleepwalking with certain prescription insomnia medicines. FDA Drug Safety Communication, April 30, 2019. fda.gov/drugs/drug-safety-and-availability/fda-adds-boxed-warning
How to Read the Evidence Tags
Every recommendation in this article on insomnia treatment carries two tags for recommendation strength and evidence quality, plus a source tag. These are Medaptly’s own simplified interpretations designed for rapid bedside use.
Recommendation Strength
| Tag | What It Means |
|---|---|
| Strong Rec | High-quality evidence broadly supports this action. |
| Moderate Rec | The weight of evidence favours this action. |
| Conditional Rec | Benefit is less certain — individualise to the patient. |
| Against | Evidence shows no benefit or potential harm. |
Evidence Quality
| Tag | What It Means |
|---|---|
| High Evidence | Multiple well-designed RCTs or high-quality meta-analyses. |
| Moderate Evidence | Single RCT or large observational studies. |
| Low Evidence | Expert consensus or small studies. |